Loading
Lucid Diagnostics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Matheis Dennis, was filed 22 Aug 2025.
Lucid Diagnostics Inc.: what insiders have been doing
This page follows insider dealings at Lucid Diagnostics Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 20 October 2025 and 20 October 2026, 11 insiders published 11 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 5,453 companies) published 22 filings over the same period, against 11 filings here. Our records for Lucid Diagnostics Inc. go back to 2021, with 3 purchases and 3 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 4.7 m USD of revenue and -58.0 m USD of net income.
There has been no open-market purchase by an insider of Lucid Diagnostics Inc. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
37
Thresholds
n/a
Buy Volume
€7M
3 ops. · all time
Sell Volume
€34,004
3 ops. · all time
Who traded when
BuySaleDennis Matheis2 buys
Since the insiders bought
- -13.8%Entry US$1.16 · Close at T+365 US$1.00
- -83.1%Entry US$10.75 · Close at T+365 US$1.82
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.37
Analyst consensus
5 analysts1.40/5
US$2.00Target US$4.00(+984%)US$9.50
Income statement
RevenueUS$4.7M
Gross profit-US$2M-42% margin
EBITDA-US$57.1M-1214% margin
Net income-US$70.6M-1499.6% margin
Valuation
PER (forward)-2.2x
P/Book6.5x
Beta1.12
Balance sheet & cash
Market capUS$70.5M
Total debtUS$25.8M
Free Cash Flow-US$46.7M
Debt / Equity228%
Profitability & ownership
ROE-556.3%
ROA-81.6%
% insiders26.5%
% institutions32.8%
Last declaration on 24 February 2026
Declarations37 total
123,000 shares0Common StockSEC:0001094891-26-000080:0
123,000 shares0Common StockSEC:0001094891-26-000073:0
123,000 shares0Common StockSEC:0001094891-26-000070:0
620,000 shares0Common stockSEC:0001094891-26-000060:0
300,000 shares0Common stockSEC:0001094891-26-000058:0
2,170,000 shares0Common StockSEC:0001094891-26-000083:0
123,000 shares0Common StockSEC:0001094891-26-000078:0
123,000 shares0Common stockSEC:0001094891-26-000077:0
123,000 shares0Common StockSEC:0001094891-26-000074:0
123,000 shares0Common StockSEC:0001094891-26-000068:0
470,000 shares0Common stockSEC:0001094891-26-000062:0
100,000 shares@ US$1.018428.9% of flowCommon StockSEC:0001062993-25-014853:0
Canonical exit: 18 Nov 2025 (T+90)
187,098 shares@ US$1.29571.1% of flowCommon StockSEC:0001062993-25-010111:0
Canonical exit: 18 Aug 2025 (T+90)
300,000 shares0Common stockSEC:0001062993-25-003169:0
300,000 shares0Common stockSEC:0001062993-25-003171:0
112,800 shares0Common StockSEC:0001062993-25-003184:0
112,800 shares0Common stockSEC:0001062993-25-003163:0
300,000 shares0Common StockSEC:0001062993-25-003218:0
112,800 shares0Common StockSEC:0001062993-25-003165:0
112,800 shares0Common StockSEC:0001062993-25-003174:0
300,000 shares0Common stockSEC:0001062993-25-003236:0
112,800 shares0Common StockSEC:0001062993-25-003193:0
112,800 shares0Common StockSEC:0001062993-25-003202:0
400,000 shares0Common stockSEC:0001062993-24-009639:0
400,000 shares0Common stockSEC:0001062993-24-009640:0
25 of 37 declarations
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a U.S.-based, commercial-stage medical diagnostics company focused on the prevention of esophageal cancer. Headquartered in New York, United States, and listed on the NASDAQ market, Lucid develops non-invasive technologies intended to detect esophageal precancer earlier, with the goal of intervening before disease progresses to invasive cancer. The company is a subsidiary of PAVmed Inc., which gives it the backing of a broader commercial-stage medtech platform. ([luciddx.com](https://www.luciddx.com/company?utm_source=openai))
Lucid’s history dates back to 2018, when it finalized a definitive licensing agreement with Case Western Reserve University covering the core technology behind its lead products. Since then, the company has reached several important milestones: FDA 510(k) clearance for EsoCheck in 2019, the commercial launch of EsoGuard as a laboratory-developed test in 2019, FDA Breakthrough Device designation for EsoGuard in 2020, and a Nasdaq IPO in 2021. Lucid also operates LucidDx Labs, a CLIA-certified, CAP-accredited laboratory that supports clinical testing operations. ([luciddx.com](https://www.luciddx.com/company?utm_source=openai))
Read moreShow less
The business is built around two complementary products. EsoCheck is an esophageal cell collection device designed for a brief, non-invasive office procedure. EsoGuard is the accompanying DNA test that analyzes the collected cells to help identify patients at risk of Barrett’s esophagus and other forms of esophageal precancer. Together, these products are positioned as a screening alternative to traditional upper endoscopy for at-risk patients, supporting Lucid’s broader prevention-focused narrative and its attempt to convert clinical adoption into recurring test-volume growth. ([ir.luciddx.com](https://ir.luciddx.com/2025-12-09-Lucid-Diagnostics-Announces-Positive-Data-from-the-Largest-Reported-Real-World-Experience-of-Esophageal-Precancer-Detection?utm_source=openai))
From a competitive perspective, Lucid occupies a specialized niche in early esophageal precancer detection. Its differentiation is based on a non-endoscopic workflow, proprietary sampling and molecular testing, and a growing body of clinical and real-world evidence. The company has highlighted support from updated NCCN guidance and American College of Gastroenterology recommendations that reference non-endoscopic biomarker testing as an acceptable alternative to invasive endoscopy in relevant settings. That said, the investment case still reflects a developing commercial-stage diagnostics company rather than a mature, scaled medtech franchise. ([ir.luciddx.com](https://ir.luciddx.com/2025-03-20-Lucid-Diagnostics-Announces-Updated-National-Comprehensive-Cancer-Network-R-NCCN-Guidelines-Now-Include-Esophageal-Precancer-Screening?utm_source=openai))
Operationally, Lucid is primarily U.S.-centric, with corporate headquarters in New York and laboratory operations in California. Recent news flow has been constructive: the company reported growing EsoGuard-related revenues, expanding health-system partnerships, stronger payer engagement, and progress in Medicare coverage discussions. In 2026, Lucid also reported a stronger cash position after recent equity financing, supporting its operating runway. For investors in French-speaking markets, LUCD is best viewed as a high-risk, high-upside U.S. NASDAQ-listed medtech name tied to the long-term adoption of preventive esophageal cancer screening. ([ir.luciddx.com](https://ir.luciddx.com/2026-05-14-Lucid-Diagnostics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
